NMD Pharma has initiated a Phase I safety, tolerability, and pharmacokinetics clinical trial of NMD1343 in healthy subjects in the UK to treat rare neuromuscular diseases.

NMD1343 is a small molecule inhibitor of ClC-1, a muscle-specific chloride ion channel.

The single and multiple ascending dose, placebo-controlled, double-blind, randomised study of NMD1343 will enrol healthy female and male volunteers.

They will be screened up to four weeks prior to receiving the dose.

Eight healthy volunteers in each cohort will initially receive either a single NMD1343 dose or a matching placebo.

NMD Pharma CEO Thomas Holm Pedersen said: “We are very pleased to announce that the first healthy subject has been dosed in this Phase I study with NMD1343.

“NMD Pharma is focused on the development of novel, first-in-class therapies for severe neuromuscular disorders, and the initiation of this study expands our clinical pipeline and our vision of delivering life-transforming therapies for those patients and their families.”

In addition, NMD Pharma is developing NMD670, which has already demonstrated positive data in treating subjects with myasthenia gravis in a Phase I and proof of mechanism trial.

NMD Pharma executive vice-president and chief medical officer Jorge Quiroz said: “It is an exciting time at NMD Pharma, now launching our second ClC-1 inhibitor NMD1343 that, with a differentiated profile compared to other development candidates in our pipeline, could be beneficial for patients with a range of rare neuromuscular diseases.”